Contact Us
Drug Search Results
More Filters [+]

PCA-062

Alternative Names: pca-062, pca062, pca 062
Latest Update: 2022-11-03
Latest Update Note: PubMed Publication

Product Description

PCA062 is a P-cadherin specific antibody-drug conjugate that utilizes the clinically validated SMCC-DM1 linker payload to mediate potent cytotoxicity in cell lines expressing high levels of P-cadherin in vitro, while displaying no specific activity in P-cadherin-negative cell lines.  (Sourced from: https://pubmed.ncbi.nlm.nih.gov/33879555/)

Mechanisms of Action: P-Cadherin Inhibitor

Novel Mechanism: Yes

Modality: Antibody Drug Conjugate

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for PCA-062

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 1: Oncology Unspecified|Esophageal Cancer|Head and Neck Cancer|Triple Negative Breast Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
JapicCTI-152921

P1

Terminated

Oncology Unspecified

2018-12-01

CPCA062X2101

P1

Completed

Head and Neck Cancer|Triple Negative Breast Cancer|Esophageal Cancer

2018-07-17

41%

Recent News Events

Date

Type

Title

11/03/2022

PubMed

 First-in-Human, Phase I Study of PCA062 in Solid Tumors-Letter.

04/01/2022

PubMed

 A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors.

07/01/2021

PubMed

 PCA062, a P-cadherin Targeting Antibody-Drug Conjugate, Displays Potent Antitumor Activity Against P-cadherin-expressing Malignancies.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions